Uncovering Missed Opportunities in Neurocrine Biosciences (NBIX)

By Emilio Sanchez • Wednesday, March 27 15:10 • Permanent Link

More and more people are talking about Neurocrine Biosciences over the last few weeks. Is it worth buying the Biotechnology stock at a price of $138.28? Only time will tell. The information below will give you a basic idea of what this investment may entail:

Neurocrine Biosciences has moved 45.4% over the last year, and the S&P 500 logged a change of 29.2%
NBIX has an average analyst rating of buy and is -8.55% away from its mean target price of $151.2 per share
Its trailing earnings per share (EPS) is $2.47
Neurocrine Biosciences has a trailing 12 month Price to Earnings (P/E) ratio of 56.0 while the S&P 500 average is 15.97
Its forward earnings per share (EPS) is $6.29 and its forward P/E ratio is 22.0
The company has a Price to Book (P/B) ratio of 6.11 in contrast to the S&P 500's average ratio of 2.95
Neurocrine Biosciences is part of the Health Care sector, which has an average P/E ratio of 30.21 and an average P/B of 4.08
NBIX has reported YOY quarterly earnings growth of 64.8% and gross profit margins of 0.7%
The company has a free cash flow of $405.08 Million, which refers to the total sum of all its inflows and outflows of cash over the last quarter
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.